VOL. XCIV, NO. 247

★ WIDE MOAT STOCKS COMPARISON ★

NO ADVICE

Stock Comparison

Abbott Laboratories vs DexCom, Inc.

Compare moat strength, market structure, and segment coverage to understand how each company defends its edge.

Abbott Laboratories

ABT · New York Stock Exchange

Market cap (USD)$160.6B
Gross margin (TTM)56.4%
Operating margin (TTM)18.2%
Net margin (TTM)13.9%
SectorHealthcare
IndustryMedical - Devices
CountryUS
Data as of2025-12-30
Moat score
64/ 100

Weighted average of segment moat scores, combining moat strength, durability, confidence, market structure, pricing power, and market share.

Full stock profile

Dive deeper into Abbott Laboratories's moat claims, evidence, and risks.

View ABT analysis

DexCom, Inc.

DXCM · Nasdaq Global Select Market

Market cap (USD)$23.6B
Gross margin (TTM)60.1%
Operating margin (TTM)19.6%
Net margin (TTM)17.9%
SectorHealthcare
IndustryMedical - Devices
CountryUS
Data as of2026-04-24
Moat score
82/ 100

Weighted average of segment moat scores, combining moat strength, durability, confidence, market structure, pricing power, and market share.

Full stock profile

Dive deeper into DexCom, Inc.'s moat claims, evidence, and risks.

View DXCM analysis

Comparison highlights

  • Moat score gap: DexCom, Inc. leads (82 / 100 vs 64 / 100 for Abbott Laboratories).
  • Segment focus: Abbott Laboratories has 7 segments (26.7% in Cardiovascular & Electrophysiology Devices); DexCom, Inc. has 1 segment (100% in Continuous glucose monitoring systems).
  • Moat breadth: Abbott Laboratories has 10 moat types across 3 domains; DexCom, Inc. has 5 across 3.

Primary market context

Abbott Laboratories

Cardiovascular & Electrophysiology Devices

Market

Cardiovascular, electrophysiology, rhythm management, structural heart and heart failure devices

Geography

Global

Customer

Hospitals, ambulatory surgery centers, cardiologists/electrophysiologists

Role

Implantable device manufacturer

Revenue share

26.7%

DexCom, Inc.

Continuous glucose monitoring systems

Market

Global continuous glucose monitoring systems and glucose biosensing devices

Geography

Global, with FY2025 revenue 71.5% United States and 28.5% international

Customer

People with diabetes, metabolic-health users, caregivers, clinicians, payors, distributors and pharmacy channels

Role

CGM device manufacturer, disposable sensor supplier, software/data platform and distribution partner

Revenue share

100%

Side-by-side metrics

Abbott Laboratories
DexCom, Inc.
Ticker / Exchange
ABT - New York Stock Exchange
DXCM - Nasdaq Global Select Market
Market cap (USD)
$160.6B
$23.6B
Gross margin (TTM)
56.4%
60.1%
Operating margin (TTM)
18.2%
19.6%
Net margin (TTM)
13.9%
17.9%
Sector
Healthcare
Healthcare
Industry
Medical - Devices
Medical - Devices
HQ country
US
US
Primary segment
Cardiovascular & Electrophysiology Devices
Continuous glucose monitoring systems
Market structure
Oligopoly
Oligopoly
Market share
n/a
35.1% (estimated)
HHI estimate
n/a
4,452
Pricing power
Moderate
Moderate
Moat score
64 / 100
82 / 100
Moat domains
Demand, Legal, Supply
Demand, Network, Legal
Last update
2025-12-30
2026-04-24

Moat coverage

Shared moat types

Brand TrustInstalled Base ConsumablesData Workflow Lockin

Abbott Laboratories strengths

Procurement InertiaGovernment Contracting RelationshipsCompliance AdvantageDistribution ControlScale Economies Unit CostTraining Org Change CostsIP Choke Point

DexCom, Inc. strengths

Ecosystem ComplementsRegulated Standards Pipe

Segment mix

Abbott Laboratories segments

Full profile >

Established Pharmaceutical Products

Competitive

12.4%

Diagnostic Products

Oligopoly

22.3%

Pediatric Nutrition

Oligopoly

9.6%

Adult Nutrition

Oligopoly

10.5%

Diabetes Care (CGM & glucose monitoring)

Duopoly

16.2%

Cardiovascular & Electrophysiology Devices

Oligopoly

26.7%

Neuromodulation Devices

Oligopoly

2.3%

DexCom, Inc. segments

Full profile >

Continuous glucose monitoring systems

Oligopoly

100%

Want the full wide moat stocks list?

Browse the full ranking of wide moat stocks, updated with moat scores and segment context.

View the moat stocks list

Looking for expansion-stage stocks?

Proven models entering the expansion stage with unit economics that work.

View expansion-stage stocks

Curation & Accuracy

This directory blends AI‑assisted discovery with human curation. Entries are reviewed, edited, and organized with the goal of expanding coverage and sharpening quality over time. Your feedback helps steer improvements (because no single human can capture everything all at once).

Details change. Pricing, features, and availability may be incomplete or out of date. Treat listings as a starting point and verify on the provider’s site before making decisions. If you spot an error or a gap, send a quick note and I’ll adjust.